Ondine Biomedical (FRA:VF5) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VF5 Ondine Biomedical Inc FRA:VF5
37 GF Score
Price €0.15
GF Value €0.09
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Ondine Biomedical Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ondine Biomedical Valuation Rank Related Terms

FRA:VF5
37GF Score
Ondine Biomedical Inc FRA:VF5
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued. The current stock price of €0.15 is trading 66.7% above its estimated GF Value™ of €0.09. GuruFocus considers Ondine Biomedical to be Significantly Overvalued.

Key valuation signals for FRA:VF5:

  • Valuation Rank:
  • GF Value™: €0.09 vs. price of €0.15 (66.7% above fair value)
  • GF Score™: 37/100 with 9 warning signs

No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ondine Biomedical Business Description

Other Exchanges OBIMF:USAOBI:UK
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
37GF Score

Get the complete analysis for FRA:VF5

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.09
GF Value